Deprenyl induces the tyrosine hydroxylase enzyme in the rat dopaminergic nigrostriatal system

Molecular Brain Research

Volumn 46, Issue 1-2, 1997, Pages 31-38

  Rodrïguez Gômez, José A ^a   Venero, José L ^a   Vizuete, María L ^a   Cano, Josefina ^a   Machado, Alberto ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

mRNA expression; Striatum; Substantia nigra; Tyrosine hydroxylase; Western blot analysis

Indexed keywords

3 O METHYLDOPAMINE; 3,4 DIHYDROXYPHENYLACETIC ACID; ANTIPARKINSON AGENT; DOPA; DOPAMINE; HOMOVANILLIC ACID; MESSENGER RNA; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; SELEGILINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; IMMUNOBLOTTING; IN SITU HYBRIDIZATION; MALE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTANTIA NIGRA;

ANIMALS; DOPAMINE; ENZYME INDUCTION; IN SITU HYBRIDIZATION; MALE; RATS; RATS, WISTAR; RNA, MESSENGER; SELEGILINE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE; VISUAL CORTEX;

EID: 0343307081     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-328X(96)00270-7     Document Type: Article

References (43)

1. Adams, J.D., Parkinson's disease and oxygen free radicals, Neurol. Forum, 4 (1993) 2-14.
2. Ames, B., Shigenaga, M.K. and Hagen, T.M., Oxidants, antioxidants and the degenerative diseases of aging, Proc. Natl. Acad. Sci. (USA), 90 (1993) 7915-7922.
3. Birkmayer, W., Knoll, J., Riederer, P. and Youdim, M.B.H., (-)Deprenyl leads to prolongation of L-DOPA efficacy in Parkinson's disease, Mod. Probl. Pharmacopsychiat., 19 (1983) 170-176.
4. Birkmayer, W., Knoll, J., Riederer, P., Hars, V. and Marton, J., Improvement of life expectancy due to L-deprenyl addition to Madopar treatment in Parkinson's disease: a long-term study, J. Neural Transm., 64 (1985) 113-127.
5. Birkmayer, W., Riederer, P., Ambrozi, L. and Youdim, M.B.H., Implications of combined treatment with Madopar and L-deprenyl in Parkinson's disease, Lancet, i (1977) 439-444.
6. Birkmayer, W., Riederer, P., Youdim, M.B.H. and Linauer, W., The potentiation of the anti-akinetic effect after L-DOPA treatment by an inhibitor of MAO-B, deprenyl, J. Neural Transm., 36 (1975) 303-326.
7. Braestrup, C., Andersen, H. and Brandrup, A., The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation, Eur. J. Pharmacol., 34 (1975) 181-187.
8. Carrillo, M.C., Kitani, K., Kanai, S., Sato, Y., Miyasaka, K. and Ivy, G.O., The effect of a long-term (6 months) treatment with (-)Deprenyl on antioxidant enzyme activities in selective brain regions in old female Fisher-344 rats, Biochem. Pharmacol., 47 (1994) 1333-1338.
9. Cesura, A.M. and Pleischer, A., The new generation of monoamine oxidase inhibitors, Prog. Drug Res., 38 (1992) 171-297.
10. Cohen, G. and Spina, M.B., Deprenyl suppresses the oxidant stress associated with increased dopamine turnover, Ann. Neurol., 26 (1989) 689-690.
11. De la Cruz C.P., Revilla, E., Steffen, V., Rodríguez-Gómez, J.A., Cano, J. and Machado, A., Protection of the aged substantia nigra of the rat against oxidative damage by (-)-deprenyl, Br. J. Pharmacol., 117 (1996) 1756-1760.
12. De la Cruz, C.P., Revilla, E., Venero, J.L., Ayala, A., Cano, J. and Machado, A., Oxidative inactivation of tyrosine hydroxylase in substantia nigra of aged rats, Free Rad. Biol. Med., 20 (1996) 53-61.
13. Dluzen, D.E. and McDermott, J.L., The effect of long-term treatment with deprenyl on basal and L-DOPA evoked dopamine release in vitro from the corpus striatum of aged rats, J. Neurol Transm., 85 (1991) 145-156.
14. Ehringer, H. and Hornykiewicz, O., Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen System, Klin. Wschr., 38 (1960) 1236-1239.
15. Finberg, J.P.M., Wang, J., Goldstein, D.S., Kopin, I.J. and Bankiewicz, K.S., Influence of selective inhibition of monoamine oxidase A or B on striatal metabolism of L-DOPA in hemiparkinsonian rats, J. Neurochem., 65 (1995) 1213-1220.
16. Grima, B., Lamoroux, A., Blanot, F., Faucon Biguet, N. and Mallet, J., Complete coding sequence of a rat tyrosine hydroxylase mRNA, Proc. Natl. Acad. Sci. (USA), 82 (1985) 617-622.
17. Harsing, L.G., Magyar, K., Tekes, K., Vizi, E.S. and Knoll, J., Inhibition by deprenyl of dopamine uptake in rat striatum: a possible correlation between dopamine uptake and acetylcholine release inhibition, Pol. J. Pharmacol. Pharm., 31 (1979) 297-307.
18. Heinonen, E.H., Savijarvi, M., Kotila, M., Hajba, A. and Scheinin, M., Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease, J. Neural Transm. (PD Sect.), 5 (1993) 193-202.
19. Karlsson, J.O., Inomata, M. and Kawashima, S., Slow axonal transport of soluble proteins and calpain in retinal ganglion cells of aged rabbits, Neurosci. Lett., 141 (1992) 127-129.
20. Kawarabayashi, T., Shoji, M., Yamaguchi, H., Tanaka, M., Harigaya, Y., Ishiguro, K. and Hirai, S., Amyloid beta protein precursor accumulates in swollen neuntes throughout rat brain with aging, Neurosci. Lett., 153 (1993) 73-76.
21. Knoll, J., The possible mechanisms of action of (-)deprenyl in Parkinson disease, J. Neural Transm., 43 (1978) 177-198.
22. Knoll, J., R-(-)-deprenyl (selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron, J. Neural Transm., 25 (Suppl.) (1987) 45-66.
23. Knoll, J., The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson' s and Alzheimer's diseases, J. Neural Transm., 40 (Suppl.) (1993) 69-91.
24. Knoll, J. and Magyar, K., Some puzzling effects of monoamine oxidase inhibitors, Adv. Biochem. Psychopharmacol., 5 (1972) 393-408.
25. Kobayasi, K., Morita, S., Sawada, H., Mizuguchi, T., Yamada, K., Nagatsu, I., Hata, T., Watanabe, Y., Fujita, K. and Nagatsu, T., Targeted disruption or the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice, J. Biol. Chem., 270 (1995) 27235-27243.
26. 4, Nature, 221 (1970) 680-685.
27. Lewis, E.J., Tank, W., Weiner, N. and Chikaraishi, D.M., Regulation of the tyrosine hydroxylase mRNA by glucocorticoid and cyclic AMP in a rat pheochromocytoma cell line, J. Biol. Chem., 258 (1983) 14632-14637.
28. Lowry, O.H., Rosebrough, N.J., Fair, A.L. and Randall, R.J., Protein measurement with the Folin phenol reagent, J. Biol. Chem., 193 (1951) 265-275.
29. Olanow, C.W., A radical hypothesis for neurodegeneration, Trends Neurosci., 16 (1993) 439-444.
30. Passinetti, G.M., Morgan, D.J., Johnson, S.A., Lerner, S.P., Myers, M.A., Poirier, J. and Finch, C.E., Combined in situ hybridization and immunocytochemistry in the assay of pharmacological effects on tyrosine hydroxylase mRNA concentration, Pharmacol. Res., 21 (1989)299-311.
31. Passineti, G.M., Osterburg, H.H., Kelly, A.B., Kohama, S., Morgan, D.G., Reinhard, Jr., J.F., Stellwagen, R.H. and Finch, C.E., Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: a model for neuron aging, Mol. Brain Res., 13 (1992) 63-73.
32. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, New York, 1986.
33. 3H]tyrosine by charcoal, Life Sci., 39 (1986) 2185-2189.
34. Tashiro, T. and Komiya, Y., Impairment of cytoskeletal protein transport due to aging or beta,beta′-iminodipropionitrile intoxication in the rat sciatic nerve, Gerontology, 40 (Suppl. 2) (1994) 36-45.
35. Tertrud, J.W. and Langston, J.W., The effect of deprenyl (selegiline) on the natural history of Parkinson's disease, Science, 245 (1989) 519-522.
36. The Parkinson Study Group, Effect of tocopherol deprenyl on the progression of disability in early Parkinson's disease, New Engl. J. Med., 328 (1993) 176-183.
37. Venero, J.L., Santiago, M., Machado, A. and Cano, J., Determination of monoamines and both forms of monoamine oxidase in the rat's substantia nigra during postnatal development, Life Sci., 45 (1989) 1277-1283.
38. Vezina, P., Mohr, E. and Grimes, D., Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects, Can. J. Neurol. Sci., 19 (1992) 142-146.
39. Vizuete, M.L., Steffen, V., Ayala, A., Cano, J. and Machado, A., Protective effect of deprenyl against 1-methyl-4-phenylpyridinium neurotoxicity in rat striatum, Neurosci. Lett., 152 (1993) 113-116.
40. Vrana, S.L., Azzaro, A.J. and Vrana, K.E., Chronic selegiline administration transiently decreases tyrosine hydroxylase activity and mRNA in the rat nigrostriatal pathway, Mol. Pharmacol., 41 (1992) 839-844.
41. Vrana, S.L., Vrana, K.E., Koves, T.R., Smith, J.E. and Dworkin, S.I., Chronic cocaine administration increases CNS tyrosine hydroxylase enzyme activity and mRNA levels and tryptophan hydroxylase enzyme activity levels, J. Neurochem., 61 (1993) 2262-2268.
42. Waldmeier, P.C. and Felner, A.E., Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment, Biochem. Pharmacol., 27 (1978) 801-802.
43. Zsilla, G., Foldi, P., Held, G., Sz'kely, A.M. and Knoll, J., The effect of repeated doses of (-)deprenyl on the dynamics of monoaminergic transmission. Comparison with chlorgyline, Pol. J. Pharmacol. Pharm., 38 (1986) 57-67.